Loading compare…
7 funds hold both · as on Jul 2026
Comparing mutual fund co-ownership helps identify hidden asset concentration. Our reverse lookup database shows that 7 mutual funds hold active equity positions in both Alembic Pharmaceuticals and GHCL. The scheme with the highest combined exposure is UTI Large & Mid Cap Fund (UTI MF), which holds a 0.44% stake in Alembic Pharmaceuticals and a 0.94% stake in GHCL, amounting to a combined conviction weight of 1.38%.
When multiple mutual funds in your portfolio double-up on the same stock pairs, it limits your diversification benefits. If you also hold either of these companies directly in your demat account, your aggregate exposure is amplified. This co-ownership pattern is standard among index-tracking products but represents active, concentrated strategies in equity schemes.
| Fund | Alembic wt. | GHCL wt. | Combined |
|---|---|---|---|
| UTI Large & Mid Cap FundUTI MF · Large & Mid Cap | 0.44% | 0.94% | |
| UTI Aggressive Hybrid FundUTI MF · Hybrid | 0.39% | 0.74% | |
| DSP Small Cap FundDSP MF · Small Cap | 0.60% | 0.50% | |
| DSP ELSS Tax Saver FundDSP MF · ELSS (Tax Saver) | 0.68% | 0.33% | |
| Back to IndexMotilal Oswal MF · Index Fund | 0.49% | 0.35% | |
| UTI Retirement FundUTI MF · Solution-Oriented | 0.25% | 0.46% | |
| IB18-Groww Nifty Total Market Index FundGroww MF · Index Fund | 0.02% | 0.02% |
These funds hold both stocks — see how much their entire portfolios overlap.
Check overlap of top funds →“Holds both” = the fund discloses an equity position in each stock in its latest public monthly portfolio (as on Jul 2026). Weight = the position as a % of that fund's portfolio. ISIN-verified from AMC disclosures. Not investment advice.